Table 2.
Clinical Outcomes of RFA vs. no RFA in NVAF patients taking DOACs
| No RFA (n=3476) | RFA (n=2661) | OR(95%CI) | P value | Adjusted OR(95%CI)b | P value | |
|---|---|---|---|---|---|---|
| Total bleeding, n(%) | 405(11.7) | 265(9.9) | 0.839(0.712-0.988) | <0.001 | 0.901(0.746-1.087) | 0.275 |
| Major Bleeding, n(%) | 98(2.8) | 15(0.6) | 0.195(0.113-0.337) | 0.035 | 0.278(0.150-0.515) | <0.001 |
| Thrombosis, n(%) | 58(1.7) | 25(0.9) | 0.559(0.349-0.896) | 0.014 | 0.535(0.316-0.908) | 0.020 |
| All-cause death, n(%) | 178(5.1) | 73(2.7) | 0.523(0.396-0.690) | <0.001 | 0.842(0.611-1.160) | 0.293 |
| Composite outcomea, n(%) | 624(18.0) | 355(15.7) | 0.704(0.611-0.810) | <0.001 | 0.835(0.710-0.982) | 0.029 |
NVAF Non-valvular atrial fibrillation, RFA Radiofrequency ablation, OR Odds ratio, 95%CI 95% Confidence interval
aComposite outcome included all-cause death, thrombosis and total bleeding
bAdjust for radiofrequency ablation, sex (male), age, body mass index, smoking, alcohol, hypertension, diabetes mellitus, heart failure, coronary artery disease, renal insufficiency, hypohepatia, vascular disease, total bilirubin, ghrelin, glutamic aminotransferase, creatinine, platelet count, hemoglobin, antiplatelet agents, proton pump inhibitors, H2 receptor antagonists, statins, amiodarone, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, digoxin, calcium blockers, diltiazem